Emerging data suggest Retatru tide , a dual agonist targeting both GLP-1 and another hormone, may offer a significant step forward for weight loss . Preliminary patient trials have demonstrated impressive losses in abdominal tissue, possibly surpassing other obesity treatments. However , more assessment is necessary to thoroughly determine its long